SCHEMBL332302

SCHEMBL332302

O=C1OC2(C3=CC=CCC13)c1cc(Cl)c(O)cc1Oc1cc(O)c(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4575132 0.88 FTO (0.34) FTO
SCHEMBL3776396 0.86
SCHEMBL215137 0.82 LMNA (0.35)
SCHEMBL315867 0.81 FTO (0.45) FTO
SCHEMBL3747895 0.81 FTO (0.35) FTO
SCHEMBL2784206 0.80 FTO (0.34) FTO
SCHEMBL147188 0.78 FTO (0.33) FTO
SCHEMBL8336070 0.75 FTO (0.32) FTO
SCHEMBL3977228 0.74 FTO (0.32) FTO
SCHEMBL4344779 0.73 FTO (0.38) FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260126387-A1 IN-SITU DETECTION METHOD FOR REACTIVE OXYGEN SPECIES BASED ON RATIOMETRIC FLUORESCENT PROBE NANJING UNIVERSITY (CN) 2026-05-07 US claimed
US-20260110698-A1 METHODS FOR QUANTIFYING FRATAXIN ACTIVITY LARIMAR THERAPEUTICS INC (US) 2026-04-23 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
US-12411145-B2 Methods for quantifying frataxin activity LARIMAR THERAPEUTICS, INC. (US) 2025-09-09 US claimed
US-20250085297-A1 METHODS FOR QUANTIFYING FRATAXIN ACTIVITY LARIMAR THERAPEUTICS, INC. 2025-03-13 US claimed
WO-2024240173-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 WO claimed
WO-2024239281-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2024-11-28 WO claimed
EP-4426741-A1 BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE Hangzhou DAC Biotech Co., Ltd. (CN) 2024-09-11 EP claimed
EP-4426727-A2 SPECIFIC CONJUGATION OF AN ANTIBODY Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 EP claimed
US-20170173168-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD. (CN) 2017-06-22 US claimed
US-20170143845-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD (CN) 2017-05-25 US claimed
US-20150322155-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE Sushou M-conj Biotech Co., Ltd (CN) 2015-11-12 US claimed
US-20150314017-A1 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD (CN) 2015-11-05 US claimed
US-20150284416-A1 NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES SUZHOU M-CONJ BIOTECH CO., LTD (CN) 2015-10-08 US claimed
WO-2009114895-A1 DIAGNOSTIC, THERAPEUTIC AND PROPHYLACTIC METHOD AND SCREENING METHOD THE UNIVERSITY OF SYDNEY (AU) 2009-09-24 WO claimed
EP-2026782-A2 N1,N4-BIS(BUTA-1,3-DIENYL)BUTANE-1,4-DIAMINE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Wisconsin Alumini Research Foundation (US) 2009-02-25 EP claimed
US-20080114072-A1 Antioxidants; polyamine oxidase inhibitors; for preventing and/or treating prostate cancer in male humans; kits WISCONSIN ALUMNI RESEARCH FOUNDATION 2008-05-15 US claimed
WO-2007130589-A2 NL, N4-BIS (BUTA-I, 3-DIENYL) BUTANE-I, 4-DIAMINE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-11-15 WO claimed
US-20040126891-A1 Method for assaying reactive oxidants in smoke BRUNSWICK LABORATORIES 2004-07-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284416-A1 NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES EPCAM, CD2BP2, CD44 FTO 4850/4885
US-20260110698-A1 METHODS FOR QUANTIFYING FRATAXIN ACTIVITY ATXN2L, XDH, CYFIP1 FTO 2876/4885
US-20170173168-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE AADAC, EPCAM, DCLRE1A FTO 4732/4885
US-20170143845-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE AADAC, EPCAM, DCLRE1A FTO 4732/4885
US-20080114072-A1 Antioxidants; polyamine oxidase inhibitors; for preventing and/or treating prostate cancer in male humans; kits BPHL, AOC1, DDO FTO 1190/4885
US-20150322155-A1 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE DCLRE1A, AADAC, UACA FTO 4499/4885
US-20260126387-A1 IN-SITU DETECTION METHOD FOR REACTIVE OXYGEN SPECIES BASED ON RATIOMETRIC FLUORESCENT PROBE CYBA, NOX4, IK FTO 658/4885
US-20150314017-A1 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE CD74, CD2, EPCAM FTO 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.